Search PubMed⌕ Search

Biomedical subjects

R Cheli

Publications and source records attributed to R Cheli.

At least 37 records · Page 2Linked to original sources
PubMed1991

[Esophageal angina].

Angina-like chest pain, caused by alterations of esophageal function, is an increasingly common occurrence confronting cardiologists: advances in pathogenetic knowledge and in diagnostic possibilities in this field have in fact shed light on the prevalence of esophageal angina, which is present in approximately 60% of patients with angiographically intact coronaries (11% of anginal patients overall). Classically, esophageal chest pain is attributed to alterations of motility or to mucosal disease (pathologic gastro-esophageal reflux of the acid, mixed or alkaline type): this last cause prevails quantitatively. Little is known of the nociceptive mechanisms triggered by these alterations: as far as mucous disease is concerned, activation of the chemosensitive receptors has been postulated, while esophageal mechanoreceptors may be activated, in the course of a motor disorder, by distension of the wall. A recently proposed additional mechanism consists in the induction of parietal esophageal ischemia by chemical or mechanical injury: it is a fascinating and potentially resolvable mechanism, which however requires further investigation. Moreover, elements of psychological nature are also involved in the genesis of esophageal pain. A diagnosis of esophageal angina, heavily conditioned by obvious considerations of prognostic order, must necessarily aim for "certainty". Prolonged monitoring of the endoluminal pH and the adoption of provocative tests, in the course of pH monitoring and manometry, play an important role in achieving this aim (ergometric test, distension induced with a balloon, edrophonium, electrostimulation, seem most effective). A promising outlook is supported by the recent introduction of prolonged manometry. Finally, diagnostic attitude must necessarily abandon its limited specialistic horizon to consider the patient's profile in its entirety.

Angina Pectoris↗
PubMed1991

A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse.

A 24-week, double-blind, randomized study at 13 centres compared the efficacy and safety of 20 mg famotidine nocte and 150 mg ranitidine h.s. for the prevention of duodenal ulcer recurrence. All participants had been successfully treated for an acute duodenal ulcer with 40 mg famotidine nocte. Patients were endoscoped at baseline and at 24 weeks, unless symptoms warranted earlier examination: of the 208 patients enrolled, 86 who received famotidine and 84 who received ranitidine met all protocol criteria and were considered evaluable. Intention to treat and per protocol analyses showed non-significant trends in favour of famotidine (P = 0.44 and 0.16, respectively). During the 24-week observation period, 16.3% of the famotidine group and 25% of the ranitidine group had an ulcer recurrence (95% CI of percentage difference -0.22 + 0.04). At 24 weeks, relief of day and night pain was reported by 81.2% and 91.8% of the famotidine-treated patients, respectively. The corresponding figures in the ranitidine group were 73.5% and 85.5%. No laboratory abnormalities related to the study-drugs were noted and only two drug related (possibly or probably) adverse experiences were reported, both in the famotidine group. The data from this study therefore, supports the conclusion that the efficacy of 20 mg famotidine nocte is comparable to that of ranitidine in preventing duodenal ulcer recurrence, with comparable tolerability for long-term therapy.

Adult↗
PubMed1991

Famotidine vs ranitidine h.s. in acute duodenal ulcer. A multicentre endoscopic trial.

A double-blind, randomized, active drug-controlled study was conducted in order to evaluate the efficacy and safety of famotidine vs ranitidine h.s. in promoting the healing of acute duodenal ulcers. Two hundred and eighty patients participated in the trial and received either famotidine 40mg h.s. or ranitidine, 300mg h.s. The two groups were not significantly different with regard to sex and risk factors such as alcohol consumption and family history of peptic ulcer disease, while in the famotidine group, there was a slightly higher number of patients who smoked. Endoscopy was performed at the end of 4 and 6 weeks in 248 patients (128 in the famotidine group and 120 in the ranitidine group). The healing rate in those receiving famotidine was 73.4% at the end of 4 weeks and increased to 93% at the end of 6 weeks, while in the ranitidine group, the rate was 75.8% and 92.5% respectively. Day and night pain markedly reduced in both groups and therapy was generally well tolerated.

Acute Disease↗
PubMed1990

Famotidine in the management of acid-reflux oesophagitis: a multicentre study.

The management of gastro-oesophageal reflux still presents a considerable problem mostly because of its multifactorial pathogenesis. In this study, we tested the response to treatment with famotidine for 8 weeks in patients with reflux oesophagitis, taking into consideration, however, only cases with pathological gastro-oesophageal reflux of the acidic type. All the patients participating in the multicentre study underwent gastro-oesophageal 24-hr pH-metry. The results show a good response to the H2 antagonist treatment with regards to both symptomatology (improvement/healing in 98% of cases, asymptomatic in 68%) and the endoscopic and histological picture. In fact, endoscopy showed complete remission of the lesions in 60% of cases and an improvement in 21%. The histological picture of oesophagitis improved in 64% of cases, 36% of which were completely healed, with no modifications in the remaining 36%. These data, which are globally better than those reported in the literature, can probably be attributed to the original selection of patients treated by means of prolonged gastro-oesophageal pH-metry, who had exclusively pathological gastro-oesophageal reflux of the acidic type. For these patients the use of the H2 antagonist drug is more appropriate even as monotherapy, than it is for those patients who have combined or isolated alkaline gastrooesophageal reflux.

Adult↗
PubMed1989

Epidemiology of duodenal erosions.

The epidemiological characters of 142 patients, 121 males and 21 females, with duodenal erosions were evaluated. They were predominantly between 30 and 60 years old. During the observation time, 125 of them were complaining of dyspeptic symptoms while the remaining 17 had haematemesis and/or melena. Duodenal erosions were single in 9 cases, zonally distributed in 51 and disseminated in 82. Erosions were associated with duodenal ulcer in 25% of cases, with ulcer scar in 4%, and with gastric ulcer in 2%. The intake of alcohol, coffee, anti-inflammatory drugs and the smoking habit were similar in patients with duodenal erosions and the general population subjected to endoscopy. These results suggest a relationship between duodenal erosions and peptic ulcer.

Adult↗
PubMed1989

Anatomic-functional profiles in duodenal ulcer.

Gastric acid secretion, gastrinemia, the type of gastritis of the fundic mucosa and the parietal cell mass, expressed by means of a 'parietal index', were considered in 70 patients with active duodenal ulcer. Hypersecretion was found in 60% of cases, normosecretion in 35.7% and hyposecretion in 4.3%, while achlorhydria was absent. Chronic fundic gastritis of the superficial or follicular type occurred at a similar rate in normosecretors (22%) and in hypersecretors (26%), being constantly of the preatrophic type in the 3 cases of hyposecretion. The parietal index was strictly correlated with maximal acid output but there was no correlation between gastrinemia and the secretory state or with the histological picture of the fundic mucosa. The results outline the prevalence of hypersecretion-hyperparietalism in duodenal ulcer but indicate also the frequent occurrence of normosecretion and normoparietalism and the rare finding of hypersecretion and hypoparietalism.

Adult↗
PubMed1989

The distribution of duodenal G cells in duodenal ulcer patients.

The number of G cells is evaluated in biopsy specimens of fundic, antral and duodenal mucosa from the bulb, second and third parts in 10 patients with duodenal ulcer, and compared with that observed in 6 normal controls. G cells are absent in fundic mucosa but in the antrum their number in duodenal ulcer patients does not differ from that of controls and is strictly related to the histological pattern of the mucosa. In the second and third duodenum of duodenal ulcer patients the number of G cells is significantly higher in comparison with controls, while in the bulb the two groups do not differ significantly. Moreover, when different duodenal portions are compared no differences in the number of G cells are observed in the duodenal ulcer group; while in controls the bulbar number of G cells is higher in comparison with second and third duodenum.

Adult↗
PubMed1988

Tripotassium dicitrate bismuthate and ranitidine in duodenal ulcer. Healing and influence on recurrence.

One hundred patients were entered into a double-blind, double-dummy comparison of tripotassium dicitrate bismuthate (TDB) versus ranitidine, to evaluate short-term healing rates, and successfully healed patients were then entered into a follow-up phase to observe relapse rates. At 4 weeks 84% of patients treated with TDB and 68% of those treated with ranitidine had healed. At 8 weeks these figures had risen to 96% and 90%, respectively (p = NS). After a year's follow-up study 84% of patients healed initially with ranitidine had relapsed, whereas in the case of patients healed initially with TDB the relapse rate was 67% (p less than 0.05). The results confirm that in the short term, TDB is as effective as ranitidine, whereas the significantly better protection against relapse offered by TDB compared with ranitidine underlines the importance of restoring mucosal defence, an approach that to date has been somewhat overlooked.

Adult↗
PubMed1988

Cytoprotective drugs: a new perspective in the treatment of adverse reactions to foods.

Food allergy (FA) and food intolerance (FI) are complex syndromes caused by adverse reactions to foods. Since mucosal permeability of the digestive tract is often increased during this pathology, we evaluated the clinical efficacy of two different cytoprotective drugs in patients with urticaria-angioedema due to FA and FI. These drugs were pirenzepine, an anti-muscarinic (anti-MI) receptor antagonist, and rosaprostol, a synthetic prostaglandin. Further, the results obtained by these schedules of treatment were compared with those achieved by the previously described polyantihistaminic treatment (ie, the association of anti-H1 plus anti-H2 receptor blockers). The present investigation suggests that the cytoprotective drugs are more effective than the antisecretive ones (ie, the anti-H2). Recently, anti-H2 drugs and ketotifen were shown to be in vitro inhibitors of the immune response and cromolyn was demonstrated capable of exerting an enhancing effect on T cell proliferation. In the present study we tested the effect of pirenzepine on several immunologic parameters, such as lymphocyte proliferation (through different activation pathways) and lymphokine (interleukin-2 and interferon-gamma) production. Since we found that pirenzepine does not affect the immune response and in consideration of its clinical efficacy, we consider this cytoprotective drug a valuable tool in the treatment of adverse reactions to foods.

Adult↗
PubMed1987

Photodynamic therapy of spontaneous animal tumors using the active component of hematoporphyrin derivative (DHE) as photosensitizing drug: clinical results.

Photodynamic therapy was performed on 25 primary spontaneous tumors in dogs and cats. The animals were injected with 2.5 mg/kg body wt. of tumor localizing fraction of hematoporphyrin derivative and treated 48 h later with laser light at 631 nm. In 5 cases the treatment was performed on the tumor bed after surgical excision of the tumor mass. An evaluation of clinical results is presented and discussed. Complete remission was obtained in 19 cases and partial remission in 6 cases.

Animals↗
PubMed1987

Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte. Italian multicentre study.

A multicentre study involving 9 Italian institutions was carried out to compare the efficacy and safety of ranitidine 150 mg b.i.d. and ranitidine 300 mg nocte in the treatment of reflux oesophagitis. 117 patients with histologically proven oesophagitis were randomly allocated to two comparable treatment groups. Efficacy and reliability were evaluated by clinical and laboratory tests at the beginning of the study, and at 3 and 6 weeks; endoscopy and biopsies were performed at the beginning and at 6 weeks. Treatment with ranitidine for 6 weeks led to total disappearance of gastro-oesophageal reflux symptoms in 60% of patients, with percentages of partial improvement varying between 85% and 95% of cases. Improvement in the results of endoscopic examination was 85%, of which 55% were cured. Microscopic examination revealed an improvement of 36% and 44%, with a cure rate of 18% and 26% respectively. With regard neither to the regression of symptoms nor to the macroscopic and microscopic inflammation of the oesophageal mucosa did statistical examination show significant differences in the therapeutic efficacy of ranitidine 150 mg b.i.d. or 300 mg nocte for treatment of reflux oesophagitis.

Adult↗
PubMed1987

Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicenter study.

A double-blind, double-dummy, randomized Italian multicenter trial was carried out to compare the efficacy and safety of omeprazole 20 mg in the morning and ranitidine 150 mg b.i.d. in short-term treatment of acute duodenal ulcer. One hundred and twenty-one patients (61 in the omeprazole and 60 in the ranitidine group) with endoscopically proven active duodenal ulcer, completed the study. The healing rates after 2, 4 and 6 weeks were 66, 97 and 100%, respectively, with omeprazole and 53, 85 and 92%, respectively, with ranitidine. The difference was statistically significant (p less than 0.05) at weeks 4 and 6. Night and day pain were markedly reduced during both treatments, as also antacid consumption. Both drugs were well tolerated, and the adverse events were infrequent and moderate. In our experience, omeprazole 20 mg once daily seems to be superior to ranitidine 150 mg b.i.d. in the short-term treatment of duodenal ulcer.

Adult↗
PubMed1986

Duodenal ulcer and chronic gastritis.

The histological aspect of fundic and antral mucosa of patients with endoscopically proven duodenal ulcer was investigated and compared with that observed in asymptomatic controls of similar age. Fundic gastritis was less frequent in ulcer patients than in controls. In contrast the chronic inflammatory lesions of the antral mucosa were more frequent, more severe and appeared at an earlier age in ulcer patients than in controls.

Adult↗
PubMed1986

Cimetidine and cytoprotection.

The actions of cimetidine are well known: an inhibitor of gastrin hydrochloric secretion, cimetidine modifies neither the motility nor any of the other functional factors. Numerous authors also attribute a cytoprotective role to cimetidine, one that is apparently carried out independently of the inhibitory effect on hydrochloric secretion. The cytoprotective mechanism itself is not yet fully understood. Numerous hypotheses have been made, including increased production of bicarbonates, inhibition of cyclic AMP, increased mucosal blood flow, and increased mucous production. However, all these hypotheses have not been fully explained, hence the problem remains open to further contributions. Well accepted, instead, is the possibility that the drug may not only intervene in acid-hydrochloric inhibition but may also, by broadening its mechanisms, enhance the powers of the mucosal barrier.

Cimetidine↗